Morgan Stanley Sellas Life Sciences Group, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Morgan Stanley holds 17,435 shares of SLS stock, worth $23,885. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,435
Previous 3,297
428.81%
Holding current value
$23,885
Previous $3,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SLS
# of Institutions
40Shares Held
5.71MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$3.14 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$1.09 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$829,1110.0% of portfolio
-
Brooklyn Fi, LLC New York, NY595KShares$815,0390.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$589,6040.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $28.2M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...